Scalable, robust in vitro models designed for integrative preclinical research.
TRUSTED / SUPPORTED BY
Despite major progress in biology and technology, preclinical research still struggles to predict what will happen in humans. This affects development time, cost, and clinical success.
Clinical Failure Rate
Most drug candidates that perform well in preclinical models fail in human trials, showing clear limits in current models.
Average cost per approved drug
Late-stage failures caused by poor early prediction significantly increase R&D costs and financial risk.
Years from lab to market
Long development timelines delay patient access and increase scientific and business risk.
To address this problem, Asemblis is developing a new in vitro modelling concept based on a simple idea: increase biological relevance without increasing operational complexity. Our approach is shaped by real needs and constraints observed in R&D labs and aims to combine bioengineering and fluidics to provide:
Bioengineered tissue models designed to reflect key human biological interactions needed for disease research and drug testing.
A design approach that avoids complex or expensive equipment, supporting easy integration into existing laboratory workflows.
An integrative framework that supports New Approach Methodologies (NAMs), in line with the FDA Modernization Act 2.0.
The goal is to generate more informative preclinical data earlier, helping teams make clearer go / no-go decisions.
*Our solution is currently in early development and is being advanced in collaboration with the Zurich University of Applied Sciences (ZHAW). At this stage, we are actively engaging with industry partners to define relevant biological readouts/endpoints and to explore feasibility studies and pilot projects.
Interested in collaborating with us? Send us a message using the form below.
FiberColl Flex® - the only fibrillar collagen bioinks on the market
Neutralized fibrillar collagen for direct cell encapsulation at physiological conditions.
Acidic variant for robust scaffolds and advanced crosslinking applications.
Founded in 2025, Bern - Switzerland
Chief Executive Officer
Chief Operations Officer
Scientific Advisor
Industry Strategy Advisor
For product questions, feasibility studies, quotes or partnership discussions, contact us using the form below. We typically reply within 24 hours.
Or email directly: contact@asemblis.com
